Skip to main content

Drug Interactions between Biktarvy and Chloromycetin Sodium Succinate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

chloramphenicol tenofovir

Applies to: Chloromycetin Sodium Succinate (chloramphenicol) and Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.

MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.

Major

chloramphenicol emtricitabine

Applies to: Chloromycetin Sodium Succinate (chloramphenicol) and Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.

MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.

Moderate

chloramphenicol bictegravir

Applies to: Chloromycetin Sodium Succinate (chloramphenicol) and Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)

Chloramphenicol may increase the blood levels of bictegravir. This may increase side effects such as diarrhea, nausea, and vomiting. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Minor

tenofovir food

Applies to: Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer